Umbilical cord blood (UCB), bone marrow (BM) and mobilized peripheral blood (mPB) are used as sources of hematopoietic stem cells for transplantation. The NOD/SCID mouse model was used to compare the lineage-specific repopulating potential of CD34 + cells derived from these sources. Six to 8 weeks after transplantation, blood, BM, spleen, liver and thymus, were harvested, and analyzed by flow cytometry using CD34, CD45, myeloid, and lymphoid lineage-specific antibodies. Fifty percent engraftment of human cells in bone marrow of mice was estimated to be reached with 0.55 × 10 6 CD34 + UCB cells or with 7.9 × 10 6 CD34 + cells from adult sources, illustrating a 10-fold superiority of UCB CD34
blood (mPB), and umbilical cord blood (UCB). The HPC source used for an individual patient may depend on the availability of the graft, the disease and the age of the patient, and the risks of complications after the transplant. For instance, transplantation with a mPB graft has been shown to result in more rapid recovery of granulocytes and platelets than BM transplantation, but is associated with a higher incidence of chronic graft-versus-host disease (GVHD). [2] [3] [4] In contrast, UCB transplantations have been reported to be accompanied by a relatively low incidence and severity of GVHD, but are associated with delayed hematopoietic recovery. 5, 6 In part, the relatively slow speed of engraftment following UCB transplantation is thought to be due to the limited numbers of HSC that can be transplanted. The limited volume of UCB that can be obtained from a single harvest results in a graft usually containing at least one log fewer CD34 + cells than a BM graft. 6, 7 However, qualitative differences in the CD34 + cell fraction from the various sources of HSC may also influence the recovery after transplantation. [8] [9] [10] [11] [12] [13] [14] The CD34 + CD38 Ϫ cell population from UCB, containing the most primitive cells essential for engraftment, showed a higher cloning efficiency, proliferated more rapidly in response to cytokine stimulation and generated more progeny than the CD34 + CD38 Ϫ cells from BM counterparts. 8 In part, the higher proliferative potential of primitive cells from UCB may be ascribed to their ability to leave the dormant state more rapidly than their BM counterparts. 14 In vivo functional differences among human stem cells from several sources have been analyzed by their capacity to engraft in NOD/SCID mice. 11, 13, 15 Several reports have indicated that the efficiency of CD34 + cells from UCB to engraft in NOD/SCID mice was 10-to 20-fold higher than CD34 + cells from adult sources. It has been hypothesized that the increased frequency of SCID mouse-repopulating cells (SRC) in UCB may compensate for the lower frequency of CD34 + cells in these grafts. In clinical transplantation, however, the high capacity of UCB CD34 + cells to engraft did not lead to rapid recovery of granulocytes and platelets. We hypothesized that the discrepancy between the high frequency of SRC and the delayed myeloid engraftment of UCB CD34
+ cells as compared to adult CD34 + cells may be due to differences in precursor cells with certain lineage-specific growth ability after transplantation.
To study such quantitative and qualitative differences in repopulating capacity of CD34 + cell populations from UCB or BM or mPB, we transplanted comparable numbers of CD34 + cells derived from these sources into NOD/SCID mice. We confirmed previous studies showing that a relatively low dose of CD34 + cells from UCB as compared to CD34 + cells from BM or mPB resulted in high engraftment levels in the NOD/SCID mice. CD34
+ cells from UCB were found to develop preferentially into cells of the B cell lineage. In contrast, we illustrated that myeloid engraftment in the NOD/SCID model in relation to the dose of CD34 + cells transplanted was comparable for UCB, BM and mPB. Our results may explain the clinical findings in UCB transplantation showing relatively high overall engraftment with high percentages and absolute numbers of B lymphocytes, [16] [17] [18] but delayed myeloid recovery caused by the relatively low numbers of CD34
+ cells transplanted, 6,7 as compared to transplantation of bone marrow grafts.
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Materials and methods
Collection and purification of CD34
+ cells from UCB, BM and mPB After informed consent, UCB was obtained at the Department of Obstetrics and Gynecology of the Bronovo Hospital, The Hague, The Netherlands. UCB from full-term normal pregnancies were collected in bags (Baxter Healthcare, Thetford, England) containing heparin. BM samples were obtained from harvests of normal donors for allogeneic transplantation. Mobilized PB samples were obtained from leukapheresis of healthy donors after mobilization of CD34 + cells by 5 days of treatment with 10 g/kg/day of recombinant human granulocyte colony-stimulating factor (rhG-CSF) (Amgen, Thousand Oaks, CA, USA).
After collection, UCB, BM and mPB samples were kept at 4°C and processed within 24 h. UCB and BM were diluted in medium consisting of RPMI 1640 supplemented with penicillin (20 U/ml), streptomycin (20 g/ml) (BioWhittaker, Verviers, Belgium) and 2% heat-inactivated fetal calf serum (v/v) (FCS) (Gibco Laboratories, Grand Island, NY, USA). Mononuclear cells were isolated following density gradient separation with Ficoll-Isopaque. Mononuclear UCB, BM or mPB samples were washed twice in medium and cryopreserved in 10% dimethylsulphoxide, 25% FCS and 65% medium. Cell samples were thawed by stepwise dilution in medium containing 40% FCS, and washed twice with medium. CD34 + cells were positively selected from the mononuclear cell suspensions by immunomagnetic cell isolation according to the manufacturer's instructions 21 + cells were also sorted from the CD34-negative fraction of UCB.
Transplantation of human CD34
+ cells into NOD/SCID mice Female NOD/LtSz-scid/scid (NOD/SCID) mice were purchased from Bomholtgard Breeding & Research Centre (Denmark) and housed in filtertop cages, which were kept in a laminar flow cabinet. The mice were given an irradiated sterile diet (Hope Farms, Woerden, The Netherlands) and acidified water containing ciprofloxacin (85 mg/l; Bayer, Leverkussen, Germany) and polymixine B (70 mg/l) ad libitum. Eight-to 12-week-old mice were sublethally irradiated (3.5 Gy) and transplanted within 24 h with CD34 + cells isolated from UCB, BM or mPB. Quantities of 10 5 to 4 ϫ 10 6 cells per mouse were injected intravenously into a lateral tail vein.
After 6-8 weeks the mice were killed by carbon dioxide inhalation. Blood was obtained by heart puncture, and collected in tubes containing heparin. Red blood cells were depleted from the blood by a 10 min incubation in NH 4 Cl (8.4 g/l)/KHCO 3 (1 g/l) buffer at 4°C. BM was collected by flushing both femurs with medium. Single cell suspensions were made from liver, spleen, thymus, lung and kidney (cell strainer 100 m; Falcon, Becton Dickinson). Cells were counted using a Sysmex F-800 (Toa Medical Electronics, Kobe, Japan). For flow cytometric analysis, cell suspensions were stained with mouse antihuman monoclonal antibodies. FITC-conjugated antibodies included monoclonal antibodies against CD45, CD2, CD4, CD15, CD34 (Becton Dickinson), and CD8 (Immunotech, Marseille, France). PE-conjugated CD34, CD38, CD33, and CD19 antibodies were obtained from Becton Dickinson, and a rabbit anti-mouse Ly-5 antibody was purchased from Pharmingen (San Diego, CA, USA). As controls, FITCconjugated and PE-conjugated mouse IgG1, IgG2a or IgG2b were used. LDS-751 was used to adjust a live gate and exclude dead cells and debris from the measurements. The cell suspensions were analyzed by a FACScan flow cytometer, of which 50 000 events were analyzed within a live gate adjusted with LDS-751.
Statistical and regression analyses
Differences between quantitative measurements between mice transplanted with UCB or mPB/BM were calculated using the Student's t-test or analysis of variance (ANOVA). A P value of Ͻ0.05 was taken to be significantly different.
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To assess the relation between the percentage of human cells found in the bone marrow of mice and the number of transplanted CD34
+ cells, we used a regression model. In order to ensure that the regression model remained between 0 and 100%, we transformed the percentage of human cells found in the bone marrow of mice using the logit transformation. To improve the goodness of fit of the regression equation the number of transplanted CD34
+ cells was logarithmically transformed. The estimated number of CD34 + cells resulting in 50% human cells in bone marrow of the mice was subsequently calculated from the (linear) regression equation.
Results
CD34 + cells isolated from UCB, BM and mPB
Flow cytometric analysis of purified CD34 + samples showed that the percentage of viable cells as determined by the LDS-751 live gate was not different for UCB, BM or mPB (69 Ϯ 18 (n = 25), 73 Ϯ 19 (n = 15), and 70 Ϯ 18 (n = 15), respectively). The purity of the viable CD34 + cells isolated from UCB, BM or mPB was 91 Ϯ 8% (n = 25), 95 Ϯ 4% (n = 15), and 93 Ϯ 5% (n = 15), respectively. In the CD34
+ cell populations of BM, UCB and mPB, no differences were observed in the percentages of CD34 + CD38 Ϫ cells (Table 1) . A low percentage of contaminating CD34
Ϫ CD38 Ϫ cells (2.2 Ϯ 1.8, n = 36) was present in the purified CD34 + samples, but these percentages did not differ between UCB, BM and mPB samples.
Human cells in BM of NOD/SCID mice after transplanting CD34
+ cells from UCB, BM or mPB + cells (P Ͻ 0.05, n = 29, 20 and 17 for UCB, BM and mPB, respectively). Similar doses of CD34 + cells gave significantly higher engraftment levels in bone marrow of NOD/SCID mice when UCB was used as a source as compared to mPB or BM (P Ͻ 0.001). Transplantation of mPB or BM CD34 + cells resulted in comparable engraftment in bone marrow of the mice, and therefore data concerning the adult sources were pooled for further analysis. Table 1 CD38 distribution within the CD34 + cell fraction of umbilical cord blood (UCB), bone marrow (BM), or mobilized peripheral blood (mPB), after purification using immuno-magnetic cell separation
CD34
+ sources % CD34
5.5 ± 3.6 83.6 ± 9.1 BM (n = 6) 6.2 ± 1.5 87.4 ± 5.9 mPB (n = 15) 7.1 ± 4.3 85.8 ± 6.8
Bone Marrow Transplantation
To calculate the number of CD34 + cells from UCB, BM and mPB resulting in 50% human CD45
+ cells in bone marrow of NOD/SCID mice, a logit transformation of the percentage of human cells in bone marrow of mice and a logarithmic transformation of the injected CD34
+ cells was performed (Figure 2b) . Although the goodness of fit of the linear regression function was relatively low, r = 0.52 and 0.50 for UCB and the adult sources, we estimated the dose of cells required for 50% engraftment using the (linear) regression of the equation. + cells found in the bone marrow were significantly higher following transplantation of UCB CD34
+ cells than following BM or mPB CD34
+ cell transplantation. Figure 3b illustrates that, at relatively low doses of UCB CD34
+ cells transplanted, the high percentages of CD45 + cells found in the bone marrow of mice were almost all CD19 + (Figure 2a vs Figure  3b ). Only following transplantation of relatively high doses of BM or mPB CD34
+ cells did significant numbers of human cells engraft. Although the majority of these cells were also B cells, a significant number of myeloid cells could be found as well. Transplantation of high doses of CD34 + cells (у1 ϫ 10 6 cells) from UCB showed similar percentages of CD33 + cells in the bone marrow of mice as compared to transplantation of BM or mPB CD34 + cells (Figure 3c ).
To confirm whether transplanting high doses of UCB CD34 + cells (у1 ϫ 10
6
) as compared to low doses resulted in significantly higher percentages of CD33 + cells in the bone marrow of mice, the percentages of CD19 + and CD33 + cells were expressed as a ratio. We used data from mice showing engraftment levels of more than 5% to exclude unreliability within the ratios. The ratio of CD19 + /CD33 + cells in the bone marrow of mice decreased significantly from 7.5 Ϯ 6 (n = 13) to 2.8 Ϯ 1.9 (n = 11) following transplantation of Ͻ1 ϫ 10 6 and у1 ϫ 10 6 of UCB CD34 + cells (P Ͻ 0.05). Transplantation of CD34 + BM or mPB cells resulted in a ratio of 4.1 Ϯ 3.9 (n = 14), which was not dependent on the number of CD34 + cells transplanted. To exclude the possibility that the observed preferential B cell engraftment in bone marrow of the NOD/SCID mice was not due to the transplantation of UCB CD34 
Human cells in various organs of NOD/SCID mice after transplantation of CD34 + cells from UCB, BM or mPB
Like the results in bone marrow of mice, significantly higher levels of human cells were found in peripheral blood, spleen, and liver when CD34 + cells from UCB were used for transplantation as compared to CD34 + cells from BM or mPB (Figure 4a + cells in blood were significantly higher following transplantation of UCB CD34
+ cells than after transplantation of CD34 + cells from adult sources (12 Ϯ 10 and 5 Ϯ 3.6, P Ͻ 0.05, respectively). For spleen and liver, percentages of 19 Ϯ 14 and 2.6 Ϯ 1.8 were found following CD34 + cell transplantation from UCB, and 3.3 Ϯ 1.9 and 0.7 Ϯ 0.3 following transplantation of CD34 + cells from the adult sources (P Ͻ 0.001 and P Ͻ 0.05, respectively).
Myeloid and lymphoid cells in various organs of mice after transplantation of CD34 + cells from UCB or adult sources
To compare lineage-specific differentiation in several organs of mice after transplantation of CD34
+ cells from UCB or adult sources, percentages of CD19 + and CD33 + cells in the organs are depicted in Figure 4c -f. Like the bone marrow, the relatively higher percentages of human cells in peripheral blood, spleen, or liver of NOD/SCID mice after UCB CD34 + cell transplantation were also due to higher B cell development (Figure 4c vs a) . BM or mPB transplanted CD34
+ cells resulted not only absolutely, but also relatively in lower percentages of B cells in peripheral blood, spleen and liver as compared to UCB CD34 + cells (Figure 4d vs c) . In contrast, no differences were found in the percentages of myeloid cells in peripheral blood or spleen after transplantation of CD34 + cells from UCB or the adult sources (Figure 4e and f) .
Discussion
Kinetic studies following transplantation of mononuclear cells from human BM or UCB into NOD/SCID mice have demonstrated that the highest numbers of all human cell types monitored were observed 6-8 weeks post transplantation. 22, 23 In the present study, therefore, we analyzed human engraftment 6-8 weeks after transplantation. We confirmed previous studies demonstrating that transplantation of CD34
+ cells from UCB resulted in higher engraftment levels in NOD/SCID as compared to CD34 + cells from BM or mPB. As calculated from logit transformation, 50% engraftment of human cells in bone marrow of the NOD/SCID mice was reached after transplantation of 5.5 × 10 5 CD34 + cells from UCB as compared to 7.9 ϫ 10 6 CD34 + cells from BM or mPB, which is a more than 10-fold difference in dose. Especially after transfer of CD34 + cells from UCB, the main cell lineage recovering in the NOD/SCID mice has been reported to be of B cells. [24] [25] [26] [27] [28] [29] Similarly, we found that after relatively low doses of UCB CD34
+ cells 81-95% of the engrafted cells were of B cell origin. At these doses only very low engraftment was found with BM or mPB CD34 + cells, not allowing reliable evaluation of specific cell lineages by flow cytometry. In contrast, no major differences in myeloid engraftment were observed after transplantation of CD34 + cells from UCB or adult sources. Relatively high doses of CD34 + cells from UCB, BM or mPB resulted in similar percentages of myeloid cells in bone marrow of NOD/SCID mice as illustrated in Figure 3 . Also, in extramedullary sites, the main difference between recovery of human cells after transfer of CD34 + cells from UCB or adult sources was observed in lymphoid development.
The differences observed were not due to contamination by CD19
+ cells from UCB, since these cells were shown not to engraft in NOD/SCID mice. In addition, no differences in contaminating CD34 Ϫ CD38 Ϫ cell populations were found between the sources. 30 + cell fraction of UCB than in that of BM or mPB. This seems to contrast to earlier findings, in which limiting dilution transplantation in NOD/SCID mice showed that human repopulating cells had multi-potential differentiation capacity, ie both lymphoid and myeloid repopulating potential. 32, 33 However, more recently, Holyoake and colleagues 11 reported that NOD/SCID mice contained detectable numbers of human B lineage cells only following transplantation of one human repopulating cell. Although we did not transplant limiting numbers of HSC in NOD/SCID mice, we suggest that a higher frequency of early progenitor cells preferentially committed to B cell development within the UCB CD34 + population as compared to the adult CD34 + population reflects the rapidly developing immune system of the newborn. 16 Although it is known that the (re)population of human cells in NOD/SCID mice is primarily due to the generation of large numbers of cells of the B cell lineage, 24, 34 it has not been emphasized that comparable numbers of CD34 + cells from UCB and adult sources resulted in similar myeloid recovery. The relatively slow engraftment of granulocytes and the significant delay in platelet recovery following UCB transplantation as compared to BM or mPB transplantation may be ascribed to the at least 10-fold lower dose of CD34 + cells with similar non-lymphoid repopulating activity. Therefore, UCB transplants may be of limited clinical use in adult patients, despite the high overall engraftment potential of UCB cells. Only by increasing the number of CD34 + cells of an UCB transplant may rapid myeloid recovery following transplantation be obtained in adult patients. Expansion of stem cells in vitro may be an option to increase the engraftment potential of UCB grafts, although maintenance or amplification of HSC in human cell cultures has yet to be conclusively demonstrated. 35 Another possibility to increase the dose of stem cells from UCB may be the use of multiple grafts for a single patient, although immunological barriers may prohibit this approach.
